Efavirenz adverse reactions: Difference between revisions
Jump to navigation
Jump to search
Ahmed Zaghw (talk | contribs) Created page with "__NOTOC__ {{Efavirenz}} {{CMG}}; {{AE}} {{AZ}} ==References== {{Reflist}} {{FDA}} Category:Antibiotics Category:Wikinfect" |
Ahmed Zaghw (talk | contribs) No edit summary |
||
| Line 3: | Line 3: | ||
{{CMG}}; {{AE}} {{AZ}} | {{CMG}}; {{AE}} {{AZ}} | ||
==ADVERSE REACTIONS== | |||
The most significant adverse reactions observed in patients treated with SUSTIVA are: | |||
* Psychiatric symptoms | |||
* Nervous system symptoms | |||
* Rash | |||
The most common (>5% in either efavirenz treatment group) adverse reactions of at least moderate severity among patients in Study 006 treated with SUSTIVA in combination with zidovudine/lamivudine or indinavir were rash, dizziness, nausea, headache, fatigue, insomnia, and vomiting. | |||
==References== | ==References== | ||
Revision as of 05:23, 2 January 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmed Zaghw, M.D. [2]
ADVERSE REACTIONS
The most significant adverse reactions observed in patients treated with SUSTIVA are:
- Psychiatric symptoms
- Nervous system symptoms
- Rash
The most common (>5% in either efavirenz treatment group) adverse reactions of at least moderate severity among patients in Study 006 treated with SUSTIVA in combination with zidovudine/lamivudine or indinavir were rash, dizziness, nausea, headache, fatigue, insomnia, and vomiting.
References
Adapted from the FDA Package Insert.